Caribou Biosciences Forecast, price target & analysts
Caribou Biosciences Target price 2026 - Analyst rating & recommendation
Caribou Biosciences Classifications & Recommendation
Caribou Biosciences Price Target
| Target Price | $10.20 |
| Price | $1.24 |
| Potential |
722.58%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Caribou Biosciences 2027 .
The average Caribou Biosciences target price is $10.20.
This is
722.58%
register free of charge
$33.60
2,609.68%
register free of charge
$4.04
225.81%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend Caribou Biosciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Caribou Biosciences stock has an average upside potential 2027 of
722.58%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 11.16 | 10.79 |
| 11.71% | 3.32% | |
| EBITDA Margin | -1,187.72% | -1,223.34% |
| 27.07% | 3.00% | |
| Net Margin | -1,327.33% | -1,034.20% |
| 11.07% | 22.08% |
8 Analysts have issued a sales forecast Caribou Biosciences 2026 . The average Caribou Biosciences sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Caribou Biosciences EBITDA forecast 2026. The average Caribou Biosciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Caribou Biosciences Analysts have issued a net profit forecast 2026. The average Caribou Biosciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.59 | -1.05 |
| 3.64% | 33.96% | |
| P/E | negative | |
| EV/Sales | 1.91 |
8 Analysts have issued a Caribou Biosciences forecast for earnings per share. The average Caribou Biosciences EPS is
This results in the following potential growth metrics and future valuations:
Caribou Biosciences...
Current Caribou Biosciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 11 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Mar 09 2026 |
| Clear Street |
Locked
➜
Locked
|
Locked | Feb 02 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 11 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Mar 09 2026 |
|
Locked
Clear Street:
Locked
➜
Locked
|
Feb 02 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 03 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
